Pfizer Inc. reported that its Phase 2 study of tilrekimig (PF‑07275315), a trispecific antibody targeting IL‑4, IL‑13, and TSLP, met its primary efficacy endpoint in adults with moderate to severe atopic dermatitis. At Week 16, 51.9% of patients receiving the middle dose achieved an Eczema Area and Severity Index 75 (EASI‑75) response, compared with 38.7% for the low dose and 49.4% for the high dose. The drug was well tolerated, with adverse event rates comparable to placebo and no dose‑dependent safety signals.
Tilrekimig’s simultaneous inhibition of three key Th2‑mediated pathways positions it as a potential first‑in‑class therapy that could offer greater efficacy than existing biologics that target only one or two pathways. The ability to block IL‑4, IL‑13, and TSLP may translate into deeper skin clearance and improved patient outcomes in a disease that affects an estimated 17 billion USD market in 2023 and is projected to reach 37 billion USD by 2034.
The positive Phase 2 data reinforce Pfizer’s strategy to diversify its portfolio beyond COVID‑19 products and to build a robust immunology pipeline. With an existing atopic dermatitis product, Cibinqo (abrocitinib), Pfizer already has a foothold in the dermatology market; tilrekimig could expand that presence and provide a differentiated option that may capture additional market share from competitors such as Dupixent, Rinvoq, and Olumiant.
Mike Vincent, Pfizer’s Chief Inflammation & Immunology Officer, said, “We are encouraged by the topline Phase 2 results for tilrekimig, which show that combining the potent inhibition of IL‑4/13 and TSLP pathways has the potential to deliver improved efficacy over the standard of care for atopic dermatitis.” He added, “We plan to advance a broad clinical development program for tilrekimig, a potential first‑in‑class trispecific antibody discovered at Pfizer, in atopic dermatitis and other Th2‑mediated inflammatory diseases including asthma and COPD.”
Pfizer intends to launch a pivotal Phase 3 trial in atopic dermatitis later in 2026, with the goal of establishing tilrekimig as a new therapeutic option in a growing market. The company also plans to explore the drug’s potential in other Th2‑driven conditions, leveraging its unique mechanism to broaden the drug’s commercial reach.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.